MC
SABSW icon

Meteora Capital’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Meteora Capital’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-35,446
Closed -$1.28K – 399
2023
Q1 		$1.28K Buy
+35,446
New +$1.99K ﹤0.01% 393

Other funds holding SABSW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Meteora Capital's SABSW Position: Q2 2023 in Review

Meteora Capital sold out of SAB Biotherapeutics Warrant (SABSW) in Q2 2023, closing a stake of 35,446 shares — an estimated $1.28K sold.

Meteora Capital first reported a position in SABSW in Q1 2023 and held it in 1 quarter. The position peaked at $1.28K in Q1 2023. 10 funds tracked by Wall St. Rank hold SABSW as of Q2 2023.

  • Meteora Capital reported no remaining SAB Biotherapeutics Warrant position as of Q2 2023 after selling out during the quarter.
  • Meteora Capital sold 35,446 SAB Biotherapeutics Warrant shares in Q2 2023, an estimated $1.28K.
  • Meteora Capital first reported a position in SAB Biotherapeutics Warrant in Q1 2023 and held it in 1 quarter.
  • Meteora Capital's SAB Biotherapeutics Warrant position peaked at $1.28K in Q1 2023.
  • 10 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q2 2023.

Based on Meteora Capital's 13F filing for Q2 2023, filed 14 Aug 2023.